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Abstract. Inhibition of epidermal growth factor receptor 
(EGFR) signalling has emerged as a new treatment strategy 
for oral squamous cell carcinoma (OSCC). Previously, we 
found that loss of EGFR expression in OSCC was associ-
ated with epithelial-mesenchymal transition (EMT), and 
may have functional implications with regard to resistance 
to cetuximab, a monoclonal anti-EGFR antibody. Eribulin (a 
microtubule inhibitor) reportedly renders breast cancer less 
aggressive, and less likely to metastasise, by triggering mesen-
chymal-to-epithelial (MET) transition. In the present study we 
evaluated whether eribulin-induced MET was associated with 
re-sensitization of resistant OSCC cell lines to cetuximab. 
In vitro antiproliferative activities were determined in three 
human OSCC lines (OSC-20, OSC-19 and HOC313) treated 
with eribulin. These three human OSCC represented different 
EMT/MET states. Interestingly, HOC313 cells (mesenchymal 
phenotype) were highly sensitive to eribulin in comparison 
with other cell lines, and significantly enhanced the anti-
proliferative effect of cetuximab in response to the drug. 
Eribulin also underwent a MET-associated gene switch that 
resulted in morphological changes and high EGFR expres-
sion in HOC313 cells, and abrogated a TGF-β-induced EMT 
gene expression signature. Eribulin-dependent sensitization 
of OSCC to cetuximab is likely due to induction of MET. 
Combination therapies based on eribulin and cetuximab have 
potential as a novel treatment regimen in OSCC.
Introduction
Epidermal growth factor receptor (EGFR/ErbB1/HER1) 
is overexpressed in a majority of oral squamous cell carci-
nomas (OSCC), and high expression levels are associated with 
a more aggressive phenotype, poor prognosis and resistance to 
cancer therapy (1). In recent years, inhibition of EGFR signal-
ling has emerged as a new treatment strategy for OSCC. A 
number of anti-EGFR antibodies (including cetuximab and 
panitumumab) and small-molecule tyrosine kinase inhibi-
tors (including gefitinib and erlotinib) that target EGFR have 
been developed (2). However, only the monoclonal antibody 
cetuximab has been approved for the treatment of advanced 
OSCC (3). Cetuximab is effective in recurrent or metastatic 
OSCC both as a first-line treatment in combination with 
platinum-based chemotherapy (4-7) and as a second-line treat-
ment in patients with platinum-refractory disease (8-10). The 
sensitivity of some tumours to cetuximab can be explained 
by the presence of mutations in the EGFR tyrosine kinase 
domain (11,12). However, such mutations are rare in OSCC (13). 
We have found that EGFR status may influence the response 
to cetuximab treatment (14). However, there are currently no 
effective treatment strategies for cetuximab-resistant OSCC in 
which EGFR expression has been downregulated.
Involvement of epithelial-mesenchymal transition (EMT) 
in drug resistance occurs in several cancer types. For instance, 
the mesenchymal marker vimentin is upregulated in specimens 
from non-small cell lung cancer (NSCLC) patients who develop 
resistance to EGFR inhibitors, suggesting that EMT has been 
triggered in such tumours (15-17). In our previous study, we 
found that loss of EGFR expression in OSCC was associated 
with EMT, and may have functional implications in the resis-
tance to cetuximab treatments (14). Yoshida et al demonstrated 
that eribulin may also render residual tumours less aggressive 
and less likely to metastasise by reversing EMT, and inducing 
a mesenchymal-to-epithelial transition (MET) (18). Eribulin is 
a non-taxane inhibitor of microtubule dynamics that exerts its 
primary pharmacologic effects by preventing normal mitotic 
spindle formation, leading to irreversible mitotic blockage 
and subsequent cell death by apoptosis (19-22). Eribulin 
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binds to the plus ends of microtubules (23), thereby disrupting 
microtubule dynamics by a mechanism distinct from those 
of other clinically used tubulin agents including epothilones, 
vinca alkaloids and taxanes. Eribulin is currently approved for 
clinical use for treatment of certain patients with advanced 
breast cancer. For instance, in the united States, Eu and Japan, 
eribulin is approved for patients with locally invasive or meta-
static breast cancer who have previously received at least two 
chemotherapeutic regimens for metastatic disease, including 
an anthracycline and a taxane (24). However, the efficacy of 
eribulin in OSCC has not yet been examined.
In the present study, we evaluated whether there were any 
correlations between eribulin-dependent MET and sensitivity 
of human OSCC cell lines to cetuximab treatment. Our find-
ings indicate that eribulin should be considered as part of a 
combination therapy to re-sensitize OSCC to cetuximab.
Materials and methods
Cell culture. Three human oral squamous cell carcinoma cell 
lines established from tumour biopsies with different invasive 
potential and EMT/MET status were obtained. These were 
OSC-20 (low-grade invasive cells, epithelial phenotype), 
OSC-19 (low-grade invasive cells, epithelial phenotype), and 
HOC313 (high-grade invasive cells, mesenchymal phenotype). 
OSC-20 is a cell line derived from a 58-year-old female 
with tongue cancer that metastasized to the cervical lymph 
nodes (25). OSC-19 was derived from a 61-year-old male 
with tongue cancer that metastasized to the cervical lymph 
nodes (26). HOC313 was derived from a 51-year-old woman 
with squamous cell carcinoma (involving the mandibular 
gingiva and oral floor) that metastasized to the cervical lymph 
nodes (27). In addition, normal human dermal fibroblast 
cells (NHDF) were used as a control. NHDF were obtained from 
the American Type Culture Collection (Manassas, VA, uSA). 
These cells were cultured in DMEM medium (Sigma-Aldrich, 
Tokyo, Japan) supplemented with 10% FBS (HyClone, Logan, 
uT, uSA). Recombinant EGF and transforming growth 
factor-β1 (TGF-β1) was purchased from R&D Systems 
(Minneapolis, MN, uSA). Eribulin (Halaven) was purchased 
from Eisai Co., Ltd. (Tsukuba, Japan). Cetuximab (Erbitux) 
was purchased from Merck Serono (Tokyo, Japan). Cetuximab 
was diluted in DMEM medium supplemented with 10% FBS 
and 100 ng/ml EGF.
Proliferation assay. Cells were plated in 96-well plates and 
cultured with the indicated concentration of compounds for 
3 days, followed by cell number and viability determinations 
as measured by CellTiter 96 AQueous One Solution Cell 
Proliferation assay (Promega, Madison, wI, uSA) according 
to the manufacturer's protocols. The optical density at 490 nm 
was measured using a microplate reader (iMark microplate 
reader; Bio-Rad, Hercules, CA, uSA). Mean IC50 values 
were calculated based on IC50 values generated from separate 
sigmoidal curves representing the growth inhibition activity 
versus eribulin concentrations in 3 independent experiments. 
The data are presented as the mean values ± SEM.
RNA extraction, cDNA synthesis and quantitative real-time 
PCR (qPCR). The levels of EGFR, E-cadherin, N-cadherin, 
vimentin and Snail1 mRNAs were analysed using a 
Rotor-Gene Q 2plex System (Qiagen, Hilden, Germany) with 
FAM/zEN/IBFQ probes (DNA sequence was not released; 
Integrated DNA Technologies, Inc., Coralville, IA, uSA). 
Total RNA was extracted with the RNeasy Protect Mini kit 
(Qiagen, Hilden, Germany) and cDNA was obtained using 
PrimeScript First Strand cDNA synthesis kit (Takara, Tokyo, 
Japan). All reactions and conditions followed the manufac-
turer's instructions. We amplified 18S rRNA as an internal 
standard using HEX/zEN/IBFQ probes (DNA sequence was 
not released; Integrated DNA Technologies, Inc.). Data were 
calculated using the ΔΔCt method for qPCR (28), which pres-
ents the data as a fold difference in expression level relative 
to a control sample; in this case, the mean expression of the 
vehicle-treated cells.
EMT induction. OSC-20 cells were seeded at 70% confluence 
and cultured for 48 or 72 h in Dulbecco's modified Eagle's 
medium (Sigma-Aldrich) with 0.5% foetal bovine serum 
(HyClone) to induce EMT. Recombinant human TGF-β1 
(R&D Systems) was added to a final concentration of 5 ng/ml.
Immunocytochemistry. Cells, cultured on cover glass 
(Matsunami, Tokyo, Japan) were fixed with 4% paraformalde-
hyde. To detect localization of EGFR in cells, mouse anti-EGFR 
antibody (Dako, Tokyo, Japan) was used for staining. The 
cells were further incubated with Alexa Fluor 488-labeled 
goat anti-mouse IgG (Cell Signaling Technology, Tokyo, 
Japan). After mounting with ProLong Gold Antifade Reagents 
(Thermo Fisher Scientific, Tokyo, Japan) the cells were 
subjected to fluorescence microscopy.
Western blot analysis. The cultured cells were lysed with 
Pierce RIPA buffer (Thermo Fisher Scientific, waltham, 
MA, uSA). Lysates mixed with sample buffer were electro-
phoretically separated and transferred onto membranes. The 
membranes were blocked with Blocking One (Nacalai Tesque, 
kyoto, Japan), followed by incubations with anti-EGFR anti-
body (Dako) and anti-human β-actin antibody (Cell Signaling 
Technology). After washing with TBS-0.05% Tween-20, 
membranes were incubated with HRP-conjugated anti-mouse 
IgG. After washing with TBS-0.05% Tween-20, membranes 
were incubated with ECL Prime western Blotting Detection 
reagent (GE Healthcare, Little Chalfont, uk). Signals were 
detected and analysed using C-DiGit (M&S TechnoSystems, 
Tokyo, Japan).
Statistical analysis. Statistical analyses were conducted using 
JMP 12.0 (SAS Institute, Inc., Cary, NC, uSA). The differ-
ences between groups were tested for statistical significance 
using the two-tailed Mann-whitney u test. Differences were 
considered significant at P<0.05.
Results
Eribulin sensitivity in OSCC cell lines. In vitro antiprolifera-
tive activities (IC50) were determined in all three OSCC lines 
treated with eribulin (Fig. 1). One day after plating, serial dilu-
tions of eribulin were added to cells for 3 days. Mean IC50 values 
for OSC-20, OSC-19 and HOC313 are 3.33, 4.15 and 0.03 nM, 
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respectively; thus, HOC313 cells are ~100 times more sensi-
tive to eribulin when compared to the other two lines.
Cetuximab sensitivity of eribulin-treated OSCC cell lines. To 
evaluate the effect of eribulin on cetuximab-resistant OSCC 
cells, we used HOC313 cells. Eribulin-treated HOC313 cells 
were incubated for 24 or 48 h with various concentrations 
of cetuximab (0, 0.005 and 0.01 µg/ml). The proliferation 
of eribulin-treated HOC313 cells was significantly inhib-
ited compared to control cells (Fig. 2A). In the absence of 
eribulin, however, cetuximab has no anti-proliferative effects 
in HOC313 cells (Fig. 2B). Conversely, in the absence of 
cetuximab, eribulin increased the proliferative index of 
HOC313 cells ~1.25-fold.
Eribulin sensitizes HOC313 cells to cetuximab by upregulating 
EGFR and inducing MET. Previously, we demonstrated that the 
HOC313 displayed a mesenchymal phenotype that was accom-
panied by loss of E-cadherin and acquisition of N-cadherin, 
vimentin and Snail expression (14). Thus, HOC313 cells were 
chosen as a model to study the effects of eribulin on MET. 
Following eribulin treatment, RNA from surviving HOC313 
cells was subjected to qPCR analysis. Eribulin treatment 
consistently upregulated expression of EGFR and E-cadherin, 
while it downregulated the mesenchymal markers N-cadherin, 
vimentin and Snail (Fig. 3A). Eribulin treated HOC313 cells 
were no longer spindle shaped like the control, but instead 
had flat, more epithelial-like morphologies (Fig. 3B). This 
conversion from mesenchymal to epithelial-like morphology 
confirmed the observed alterations in EMT/MET-related 
genes (Fig. 3A). Upregulation of EGFR was confirmed at the 
protein level by immunocytochemistry (Fig. 3B) and immu-
noblotting (Fig. 3C).
Eribulin downregulates genes induced by TGF-β signalling. 
The above results suggest that eribulin can transcriptionally 
reprogram cells in order to achieve MET. To study this in more 
detail, we asked whether eribulin could prevent the reverse 
process (i.e., EMT) that is induced by the cytokine TGF-β. For 
Figure 1. Eribulin sensitivity of oral squamous cell carcinoma (OSCC) cell 
lines with different invasive capabilities. In vitro antiproliferative activi-
ties (IC50) were determined in all three OSCC lines treated with eribulin. 
IC50 values for OSC-20, OSC-19 and HOC313 were 3.33, 4.14 and 0.07 nM, 
respectively. The data are presented as the mean values ± SEM from tripli-
cate experiments.
Figure 2. Cetuximab inhibited proliferation of eribulin-pretreated cell lines. 
(A) Eribulin pretreated or (B) non-treated HOC313 cells were incubated with 
various concentrations of cetuximab as indicated and the anti-proliferative 
effect of cetuximab was determined using an MTT assay. Each data point 
represents the mean of three independent experiments. The vertical bars 
show standard deviations. Error bars correspond to SEM. *P<0.05.
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this, we used OSC-20 cells, as they have an epithelial pheno-
type, and undergo EMT in response to TGF-β (14). Following 
treatment with TGF-β and/or eribulin, the expression profiles 
of epithelial and mesenchymal markers were analysed (Fig. 4). 
Eribulin inhibited TGF-β-dependent downregulation of 
E-cadherin and also prevented upregulation of the mesen-
chymal markers N-cadherin, vimentin and Snail. Interestingly, 
eribulin treatment alone had no effect on MET.
Discussion
we found that cetuximab-resistant cells with a mesenchymal 
phenotype are particularly sensitive to eribulin. EMT is a 
process in which epithelial cells acquire mesenchymal proper-
ties and show loss of intercellular cohesion, increased cellular 
migration, and increased resistance to anticancer agents. 
Importantly, the EMT signature correlates with eribulin resis-
tance in breast cancer cells in vitro (29), cisplatin resistance 
in ovarian cancer (30,31), and resistance to gemcitabine, 5-Fu 
and cisplatin in pancreatic cancer (32). Our previous study 
demonstrated that the EMT-associated genes N-cadherin, 
vimentin and Snail were upregulated in HOC313 cells (14). 
We report that an EMT gene expression profile is a predictor 
of eribulin sensitivity in OSCC, which contrasts with previous 
findings in other tumour types. While the molecular mecha-
nisms that account for this difference remain to be determined, 
we suggest that they may be confined to cancer subtypes with a 
unique molecular profile. Clearly, further investigation will be 
required to test this hypothesis.
Involvement of EMT in resistance to EGFR inhibitors has 
been reported in several cancer types. For instance, specimens 
from NSCLC patients who develop resistance to EGFR inhibi-
tors are vimentin-positive, suggesting that EMT has been 
triggered in such tumours (15-17). In our previous study, the 
EMT-associated genes, N-cadherin, vimentin and Snail were 
upregulated in cetuximab-resistant OSCC cells (14). we also 
demonstrated that TGF-β induced EMT in an OSCC cell line 
(OSC-20) that correlated with loss of EGFR expression, and 
a phenotypic switch from cetuximab-sensitive to cetuximab-
resistant (14). This is consistent with reports that the response 
to EGFR-targeted agents is inversely correlated with EMT 
in tumours without known EGFR mutations, including 
OSCC, NSCLC, bladder, colorectal, pancreas and breast 
carcinomas (33-37). Yoshida et al demonstrated that eribulin 
promoted a shift from EMT to MET in breast carcinoma 
cells in vitro (18). Thus, we investigated potential relation-
ships between eribulin-dependent switches in the EMT/MET 
balance and sensitivity to EGFR inhibitors in OSCC. we 
found that eribulin sensitizes HOC313 cells to cetuximab 
by inducing MET, thus revealing a novel biological activity 
Figure 3. Eribulin treatment of HOC313 cells in vitro induces mesenchymal-
epithelial transition (MET). HOC313 cells were treated with eribulin 
or control vehicle for 5 days, at the IC50 doses of eribulin. (A) Relative 
expression levels of epidermal growth factor receptor (EGFR) and the 
epithelial-mesenchymal transition (EMT)-associated genes E-cadherin, 
N-cadherin, vimentin and Snail mRNAs in eribulin-treated HOC313 cell 
lines. Expression levels are displayed as fold differences relative to the 
vehicle-treated controls. (B) Representative images of HOC313 cells fol-
lowing treatment with eribulin. Alexa Fluor 488-labelled anti-mouse IgG was 
used to detect EGFR antibody (green). Scale bar, 50 µm. (C) Expression of 
EGFR protein as assessed by immunoblot analysis. Arrow indicates EGFR, 
and β-actin was used as a loading control.
Figure 4. Eribulin antagonizes transforming growth factor-β1 (TGF-β) sig-
nalling. OSC-20 cells were treated with TGF-β and eribulin (at the IC50 dose 
of 3.33 nM) or the single agents for 48 or 72 h. Relative expression levels 
of epithelial-mesenchymal transition (EMT)-associated genes E-cadherin, 
N-cadherin, vimentin and Snail mRNAs are shown. The expression levels 
are displayed as fold differences relative to vehicle-treated controls.
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associated with eribulin. Eribulin-induced MET is associated 
with upregulation of EGFR, providing a plausible explanation 
for the sensitization to cetuximab. However, further studies 
are necessary to elucidate the precise molecular mechanisms 
governing this cetuximab sensitivity.
Eribulin treatment prevents TGF-β-dependent induction 
of an EMT signature, suggesting that eribulin-dependent 
MET was, at least in part, due to inhibition of TGF-β signal-
ling (Fig. 4). Several studies indicate that the primary targets 
of eribulin are tubulin and microtubules (19-21,23,38). Smad 
proteins, which are essential mediators of the TGF-β signal-
ling pathway, normally bind microtubules in the absence of 
TGF-β but dissociate from them upon TGF-β stimulation (39). 
Dissociated Smad2 and Smad3 become phosphorylated and 
then associate with Smad4, followed by translocation of the 
entire complex to the nucleus where it activates transcrip-
tion. Eribulin inhibits the growth phase of microtubule 
dynamics (38) by binding to high-affinity sites on microtubule 
plus ends (23). This may stabilize the association between 
Smad proteins and microtubules, and consequently inhibit 
Smad phosphorylation and activation. However, we cannot 
exclude the possibility that eribulin may target other molecules 
in order to promote MET. It would be interesting to determine 
whether other tubulin-targeting agents, such as the taxanes, 
vinca alkaloids, or epothilones, have similar effects on the 
EMT/MET balance.
In conclusion, we have shown that eribulin can increase the 
sensitivity to cetuximab by inducing MET in cetuximab-resis-
tant OSCC, and that this is correlated with suppression 
of TGF-β signalling in epithelial type OSCC. Therefore, 
combination therapies with eribulin and cetuximab should 
be considered as a new treatment regimen for both epithelial 
and mesenchymal type OSCC. we hope that the results of the 
present study will provide an impetus for future investigations 
of novel treatment strategies for OSCC.
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